Splenosis Mimicking Recurrence of Renal Cell Carcinoma after Radical Nephrectomy: A Case Report

Abstract

Objective. To investigate the efficacy of surgery in the treatment of metastatic renal cell carcinoma (mRCC) and to identify prognostic factors. Methods. A single center retrospective study of 96 patients with mRCC from December 2004 to August 2013. Results. The median follow-up time was 45 months. Thirty-one (32.3%) of the patients received complete resection of metastatic sites, 11 (11.5%) of the patients underwent incomplete resection of metastatic sites, and 54 (56.3%) of the patients received no surgery. In the univariate Kaplan-Meier analysis, the median overall survival times of the three groups were 52 months, 16 months, and 22 months, respectively ( < 0.001). The difference in the overall survival time was statistically significant between complete resection and no surgery groups (HR = 0.43, = 0.009), while there was no significant difference between the incomplete metastasectomy and no surgery groups (HR = 1.80, = 0.102). According to the multivariate Cox regression analysis, complete metastasectomy (HR = 0.49, = 0.033), T stage > 3 (HR = 1.88, = 0.015), disease free interval <12 months (HR = 2.34, = 0.003), and multiorgan involvement (HR = 2.00, = 0.011) were significant prognostic factors. Conclusion. In the era of targeted therapy, complete metastasectomy can improve overall survival. Complete metastasectomy, T stage > 3, disease free interval <12 months, and multiorgan involvement are independent prognostic factors.